OJRD  Vol.3 No.2 , May 2013
A Case of DIPNECH and Review of the Current Literature
ABSTRACT
Diffuse Idiopathic Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare pulmonary disease. It was first described by Aguayo et al. in 1992, and recognised by the World Health Organisation in 2004 as a precursor lesion to the development of pulmonary carcinoid tumour. DIPNECH has been described in several isolated case reports and series. This article describes a case of DIPNECH and summaries the recent literature in an attempt to raise awareness of this disease and management options.

Cite this paper
P. Mitchell, M. Kennedy and M. Henry, "A Case of DIPNECH and Review of the Current Literature," Open Journal of Respiratory Diseases, Vol. 3 No. 2, 2013, pp. 68-72. doi: 10.4236/ojrd.2013.32011.
References
[1]   W. D. Travis, E. Brambilla, H. K. Muller-Hermlink and C. C. Harris, “Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart,” In: World Health Organization Classification of Tumours, Lyon, 2004.

[2]   K. M. Kerr, “Pulmonary Preinvasiveneoplasia,” Journal of Clinical Pathology, Vol. 54, No. 4, 2001, pp. 257-271. doi:10.1136/jcp.54.4.257

[3]   M. G. Carmichael and L. L. Zacher, “The demonstration of Pulmonary Neuroendocrine Cell Hyperplasia with Tumorlets in a Patient with Chronic Cough and a History of Multiple Medical Problems,” Military Medicine, Vol. 170, No. 5, 2005, pp. 439-441.

[4]   J. Swigris, S. Ghamande, T. Rice and C. Farver, “Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. An Interstitial Lung Disease with Airway Obstruction,” J Bronch, Vol. 12, 2005, pp. 62-64. doi:10.1097/01.laboratory.0000147030.83001.3c

[5]   S. J. Davies, J. R. Gosney, D. M. Hansell, A. U. Wells, R. M. du Bois, M. M. Burke, M. N. Sheppard and A. G. Nicholson, “Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: An Under-Recognised Spectrum of Disease,” Thorax, Vol. 62, No. 3, 2007, pp. 248-252. doi:10.1136/thx.2006.063065

[6]   M. C. Aubry, C. F. Thomas Jr., J. R. Jett, S. J. Swensen and J. L. Myers, “Significance of Multiple Carcinoid Tumors and Tumorlets in Surgical Lung Specimens: Analysis of 28 Patients,” Chest, Vol. 131, No. 6, 2007, pp. 1635-1643. doi:10.1378/chest.06-2788

[7]   R. R. Miller and N. L. Muller, “Neuroendocrine Cell Hyperplasia and Obliterative Bronchiolitis in Patients with Peripheral Carcinoid Tumors,” American Journal of Surgical Pathology, Vol. 19, No. 6, 1995, pp. 653-658. doi:10.1097/00000478-199506000-00005

[8]   E. Seregni, L. Ferrari, E. Bajetta, A. Martinetti and E. Bombardieri, “Clinical Significance of Blood Chromogranin a Measurement in Neuroendocrine Tumours,” Annals of Oncology, Vol. 12, Suppl. 2, 2001, pp. S69-S72. doi:10.1093/annonc/12.suppl_2.S69

[9]   J. S. Lee, K. K. Brown, C. Cool and D. A. Lynch, “Diffuse Pulmonary Neuroendocrine Cell Hyperplasia: Radiologic and Clinical Features,” Journal of Computer Assisted Tomography, Vol. 26, No. 2, 2002, pp. 180-184. doi:10.1097/00004728-200203000-00003

[10]   A. Gorshtein, D. Gross, D. Barak, Y. Strenov, Y. Refaeili, I. Shimon and S. Grozinsky-Glasinshy, “Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia and the Associated Lung Neuroendocrine Tumours: Clinical Experience with a Rare Entity,” Cancer, Vol. 118, No. 3, 2012, pp. 612-619. doi:10.1002/cncr.26200

[11]   S. Dacic, “Pulmonary Preneoplasia,” Archives of Pathology & Laboratory Medicine, Vol. 132, No. 7, 2008, pp. 1073-1078.

[12]   A. Nasser, D. Jaroszewski, R. Helmers and T. Colby, “Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Systematic Overview,” American Journal of Respiratory and Critical Care Medicine, Vol. 184, No. 18-16, 2011, pp. 8-16.

[13]   J. R. Gosney, I. J. Williams, A. R. Dodson and C. S. Foster, “Morphology and Antigen Expression Profile of Pulmonary Neuroendocrine Cells in Reactive Proliferations and Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH),” Histopathology, Vol. 59, No. 4, 2011, pp. 751-762. doi:10.1111/j.1365-2559.2011.03992.x

[14]   S. Degan, G. Y. Lopez, K. Kevill and M. E. Sunday, “Gastrin-Releasing Peptide, Immune Responses, and Lung Disease,” Annals of the New York Academy of Sciences, Vol. 1144, 2008, pp. 136-147. doi:10.1196/annals.1418.022

[15]   EGFR, “Expression in Pulmonary Neuroendocrine Cell Hyperplasia,” Pathologe, Vol. 27, No. 2, 2006, pp. 147-151. doi:10.1007/s00292-006-0819-0

[16]   A. Warth, E. Herpel, A. Schmahl, K. Storz and P. A. Schnabel, “Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in Association with an Adenocarcinoma: A Case Report,” Journal of Medical Case Reports, Vol. 2, 2008, p. 21. doi:10.1186/1752-1947-2-21

[17]   L. Salz, “Octreotide as an Antineoplastic Agent in the Treatment of Functional and Nonfunctional Neuroendocrine Tumors,” Cancer, Vol. 72, No. 1, 1993, pp. 244-248. doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q

[18]   J. Chan and M. Kulke, “Progress in the Treatment of Neu- roendocrine Tumors,” Current Oncology Reports, Vol. 11, No. 3, 2009, pp. 193-199. doi:10.1007/s11912-009-0028-0

[19]   M. B. Fessler, C. D. Cool, Y. E. Miller, M. I. Schwarz and K. K. Brown, “Idiopathic diffuse Hyperplasia of Pulmonary Neuroendocrine Cells in a Patient with Acromegaly,” Respirology, Vol. 9, No. 2, 2004, pp. 274-277. doi:10.1111/j.1440-1843.2004.00571.x

[20]   M. S. Sanaee, P. M. O’Byrne and P. Nair, “Diffuse Idiopathic Pulmonary Neuroendocrine Hyperplasia, Chronic Eosinophilic Pneumonia, and Asthma,” European Respiratory Journal, Vol. 34, No. 6, 2009, pp. 1489-1492. doi:10.1183/09031936.00109409

[21]   E. N. Coletta, L. R. Voss, M. S. Lima, J. S. Arakaki, J. Camara, C. D’Andretta Neto and C. A. Pereira, “Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia Accompanied by Airflow Obstruction,” Jornal Brasileiro de Pneumologia, Vol. 35, No. 5, 2009, pp. 489-494.

[22]   S. M. Aguayo, Y. E. Miller, J. A. Waldron Jr., R. M. Bogin, M. E. Sunday, G. W. Staton Jr, W. R. Beam and T. E. King Jr., “Brief Report: Idiopathic Diffuse Hyperplasia of Pulmonary Neuroendocrine Cells and Airways Disease,” New England Journal of Medicine, Vol. 327, 1992, pp. 1285-1288. doi:10.1056/NEJM199210293271806

[23]   L. Saltz, “Octreotide as an antineoplastic Agent in the Treatment of Functional and Non-Functional Neuroendocrine Tumours,” Cancer, Vol. 72, No. 1, 1993, pp. 244-248. doi:10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q

[24]   J. Chan and M. Kulke, “Progress in the Treatment of Neuroendocrine Tumors,” Current Oncology Reports, Vol. 11, No. 3, 2009, pp. 193-199. doi:10.1007/s11912-009-0028-0

 
 
Top